BHARAT IMMUNOLOGICALS (India) Financial Indicators Patterns

We suggest you to use BHARAT IMMUNOLOGICALS BIOLOG fundamental analysis to find out if markets are at this time mispricing the company. Strictly speaking you can use it to find out if BHARAT IMMUNOLOGICALS is indeed mispriced or if you can make any profits on it by purchasing it and then waiting for the market to recognize its mistake and reprise the security. We found twenty-three available financial indicators for BHARAT IMMUNOLOGICALS which can be compared to its peers in the sector. To make sure the equity is not overpriced, please confirm all BHARAT IMMUNOLOGICALS BIOLOG fundamentals including its Operating Margin, Revenue, Debt to Equity, as well as the relationship between Price to Earning and Net Income .
49%49%

Chance of Financial Distress

BHARAT IMMUNOLOGICALS BIOLOG has less than 49 (%) percent chance of experiencing financial distress in the next 2 years of operations. More Info

BHARAT IMMUNOLOGICALS Company Summary

BHARAT IMMUNOLOGICALS competes with Baroda ELSS. Bharat Immunologicals Biologicals Corporation Limited, a biotechnology company, manufactures and markets a range of pharmaceuticals products in India. The company was founded in 1989 and is based in Bulandshahr, India. BHARAT IMMUNOLOGICALS operates under Biotechnology classification in India and is traded on Bombay Stock Exchange.

BHARAT IMMUNOLOGICALS Shares Outstanding vs Current Valuation

BHARAT IMMUNOLOGICALS BIOLOG is number one stock in shares outstanding category among related companies. It is the top company in current valuation category among related companies reporting about  5.83  of Current Valuation per Shares Outstanding.

BHARAT IMMUNOLOGICALS Market Fundamentals

Follow Benchmarks with Macroaxis syndicated feed, custom widget, or your favorite custom stock ticker
See also Trending Equities. Please also try Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Search macroaxis.com